JCT  Vol.5 No.12 , October 2014
The Relation between the Initial Type of Schedule Used to Administer Doxorubicin and Long-Term Doxorubicin Cardiotoxicity
ABSTRACT
Background: As more patients survive cancer chemotherapy, problems associated with the late complications of therapy have become increasingly apparent; late doxorubicin cardio-myopathy being one of the most pressing. The relationship between initial dose, schedule employed, and etiology are still not well defined. This study attempts to clarify some of these issues. Methods: Patients receiving large total doses of doxorubicin by schedules designed to minimize peak drug levels were monitored in regard to their cardiac status for up to 31 years following completion of doxorubicin therapy. A computer program predicting the amount of doxorubicin retained by the heart vs. schedules employed was devised with the predictions of the computer program being compared to the clinical findings. Results: 1365 patients receiving doses of doxorubicin greater than 610 mgm./M2 were monitored for up to 31 years following completion of such therapy. No patient developed unequivocal clinical and pathologic evidence of a doxorubicin related cardiomyopathy. Knowing that human cardio-myocytes contain enzymes capable of neutralizing doxorubicin, a computer program predicted that by increasing their efficiency, the schedules employed substantially l decreased the relative amount of drug retained by the heart, findings compatible with both animal experiments and clinical results. Conclusions: administration of doxorubicin by schedules in which peak plasma levels of drug were minimized resulted in marked decreases in both acute and long-term cardiac toxicity; believed to be due to potentiation of myocardial enzymes capable of inactivating the drug.

Cite this paper
Weiss, A. , Stoloff, I. , Simoes, A. and Lackman, R. (2014) The Relation between the Initial Type of Schedule Used to Administer Doxorubicin and Long-Term Doxorubicin Cardiotoxicity. Journal of Cancer Therapy, 5, 1145-1152. doi: 10.4236/jct.2014.512117.
References
[1]   Ad?o, R., de Keulenaer, G., Leite-Moreira, A. and Brás-Silva, C. (2013) Cardiotoxicity Associated with Cancer Therapy: Pathophysiology and Prevention Strategies. Revista Portuguesa de Cardiologia, 32, 395-409. http://dx.doi.org/10.1016/j.repc.2012.11.002

[2]   Lefrak, E.A., Pitha, J., Rosenheim, S. and Gottlieb, J.A. (1973) A Clinicopathologic Analysis of Adriamycin Cardiotoxicity. Cancer, 32, 302-314.
http://dx.doi.org/10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2

[3]   Weiss, A.J. and Manthel, R.W. (1977) Experience with the Use of Adriamycin in Combination with Other Anticancer Agents Using a Weekly Schedule, with Particular Reference to Lack of Cardiac Toxicity. Cancer, 40, 2046-2052.
http://dx.doi.org/10.1002/1097-0142(197711)40:5<2046::AID-CNCR2820400508>3.0.CO;2-5

[4]   Von Hoff, D.D., Layard, M.W., Basa, P., Davis Jr., H.L., Von Hoff, A.L., Rozencweig, M. and Muggia, F.M. (1979) Risk Factors for Doxorubicin-Induced Congestive Heart Failure. Annals of Internal Medicine, 91, 710-717. http://dx.doi.org/10.7326/0003-4819-91-5-710

[5]   Swain, S.M., Whaley, F.S. and Ewer, M.S. (2003) Congestive Heart Failure in Patients Treated with Doxorubicin: A Retrospective Analysis of Three Trials. Cancer, 97, 2869-2879.
http://dx.doi.org/10.1002/cncr.11407

[6]   Zhang, J.Q., Honbo, N. and Karlinger, J.S. (2010) Doxorubicin Cardiomyopathy. Cardiology, 115, 155-162 http://dx.doi.org/10.1159/000265166

[7]   Elbl, L., Hrstkova, H., Chaloupka, V., Novotny, J. and Michalek, J. (2003) The Evaluation of Left Ventricular Function in Childhood Cancer Survivors by Pharmacological Stress Echocardiography. Neoplasma, 50, 191-197.

[8]   Torti, F.M., Bristow, M.R., Howes, A.E., Aston, D., Stockdale, F.E., Carter, S.K., Kohler, M., Brown Jr., B.W. and Billingham, M.E. (1983) Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule. Assessment by Endomyocardial Biopsy. Annals of Internal Medicine, 99, 745-749.
http://dx.doi.org/10.7326/0003-4819-99-6-745

[9]   Mads, D. and Else, K. (1983) Hoffmann Doxorubicin (Adriamycin) Transport in Ehrlich ascites Tumour Cells: Comparison with Transport in Human Red Blood Cells. Scandinavian Journal of Laboratory and Clinical Medicine, 43, 241-248.

[10]   Kerr, D.J., Kerr, I.M., Freshney, R.I. and Kaye, S.B. (1986) Comparative Intracellular Uptake of Adriamycin and 4’-Deoxydoxorubicin by Nonsmall Cell Lung Tumor Cells in Culture and Its Relationship to Cell Survival. Biochemical Pharmacology, 35, 2817-282.
http://dx.doi.org/10.1016/0006-2952(86)90195-4

[11]   Hu, M., Liu, Y.P., Deng, C.H., Han, R.F., Jia, Y.H., Liu, S.W., Jiang, Z.M., Cao, X.C., He, L. and Zhang, Q.P. (2011) Enhanced Invasiveness in Multidrug Resistant Leukemic Cells Is Associated with Overexpression of P-Glycoprotein and Cellular Inhibitor of Apoptosis Protein. Leukemia & Lymphoma, 52, 1302-1311. http://dx.doi.org/10.3109/10428194.2011.572323

[12]   Seibert, E. and Tracy, T.S. (2014) Different Enzyme Kinetic Models. Methods in Molecular Biology, 1113, 23-35. http://dx.doi.org/10.1007/978-1-62703-758-7_3

[13]   Weiss, A.J., Barrueco, C.J., Kocsis, J.J. and Bianchi, C.P. (1984) Doxorubicin Efflux from Isolated Rat Hearts at 37% and 25% C. Federation of American Societies for Experimental Biology (Pharmacology), 5, 53.

[14]   Weiss, A.J., Barrueco, C.J., Kocsis, J.J. and Bianchi, C.P. (1985) Doxorubicin Transport Using an Improved Preparation of Calcium Proc Resistant Cardiac Myocytes from Adult Rats. American Society for Pharmacology and Experimental Therapeutics, 234, 166.

[15]   McCaffrey, T.A., Tziros, C., Lewis, J., Katz, R., Siegel, R., Weglicki, W., Kramer, J., Mak, I.T., Toma, I., Chen, L., Benas, E., Lowitt, A., Rao, S., Witkin, L., Lian, Y., Lai, Y., Yang, Z. and Fu, S.W. (2013) Genomic Profiling Reveals the Potential Role of TCL1A and MDR1 Deficiency in Chemotherapy-Induced Cardiotoxicity. International Journal of Biological Sciences, 9, 350-360.
http://dx.doi.org/10.7150/ijbs.6058

[16]   Maurício, K.S., Lino, O.P., Elza, S.M., Damiana, V.R., Juliane, R.S., Bibiana, A.S. and Mariana, R.F. (2006) MRPI/ GS-X Pump ATPase Expression Is This the Explanation for the Cytoprotection of the Heart against Oxidative StressInduced Redox Imbalance in Comparison to Skeletal Muscle Cells? Cell Biochemistry and Function, 25, 23-32.

[17]   Hasinoff, B.B., Patel, D. and Wu, X. (2013) The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin. Cardiovascular Toxicology, 13, 33-47. http://dx.doi.org/10.1007/s12012-012-9183-x

[18]   Couture, L., Nash, J.A. and Turgeon, J. (2006) The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart. Pharmacological Reviews, 58, 244-258. http://dx.doi.org/10.1124/pr.58.2.7

[19]   Wang, J., Nachtigal, M.W., Kardami, E. and Cattini, P.A. (2013) FGF-2 Protects Cardiomyocytes from Doxorubicin Damage via Protein Kinase C-Dependent Effects on Efflux Transporters. Cardiovascular Research, 98, 56-63. http://dx.doi.org/10.1093/cvr/cvt011

[20]   Valko, P. and Vajda, S. (1989) Advanced Scientific Computing in Basic with Applications in Chemistry, Biology and Pharmacology (Data Handling in Science and Technology). Elsevier, Amsterdam, 268.

[21]   Pacciarini, M.A., Barbieri, B., Colombo, T., Broggini, M., Garattini, S. and Donelli, M.G. (1978) Distribution and Antitumor Activity of Adriamycin Given in a High Dose and a Repeated Low-Dose Schedule to Mice. Cancer Treatment Reports, 62, 791-800.

[22]   Lipshultz, S.E., Giantris, A.L., Lipsitz, S.R., Kimball Dalton, V., Asselin, B.L., Barr, R.D., Clavell, L.A., Hurwitz, C.A., Moghrabi, A., Samson, Y., Schorin, M.A., Gelber, R.D., Sallan, S.E. and Colan, S.D. (2002) Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol. Journal of Clinical Oncology, 20, 1677-1682.
http://dx.doi.org/10.1200/JCO.20.6.1677

[23]   Berrak, S.G., Ewer, M.S., Jaffe, N., Pearson, P., Ried, H., Zietz, H.A. and Benjamin, R.S. (2001) Doxorubicin Cardiotoxicity in Children: Reduced Incidence of Cardiac Dysfunction Associated with Continuous-Infusion Schedules. Oncology Reports, 8, 611-614.

[24]   Drafts, B.C., Twomley, K.M., D'Agostino Jr., R., Lawrence, J., Avis, N., Ellis, L.R., Thohan, V., Jordan, J., Melin, S.A., Torti, F.M., Little, W.C., Hamilton, C.A. and Hundley, W.G. (2013) Low to Moderate Dose Anthracycline-Based Chemotherapy Is Associated with Early Noninvasive Imaging Evidence of Subclinical Cardiovascular Disease. JACC: Cardiovascular Imaging, 6, 877-885.
http://dx.doi.org/10.1016/j.jcmg.2012.11.017

[25]   Lipshultz, S.E., Lipsitz, S.R., Sallan, S.E., Dalton, V.M., Mone, S.M., Gelber, R.D. and Colan, S.D. (2005) Chronic Progressive Cardiac Dysfunction Year after Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 23, 2629-2636.
http://dx.doi.org/10.1200/JCO.2005.12.121

[26]   Ali, M.K., Ewer, M.S., Gibbs, H.R., Swafford, J. and Graff, K.L. (1994) Late Doxorubicin-Associated Cardiotoxicity in Children. The Possible Role of Intercurrent Viral Infection. Cancer, 74, 182-188. http://dx.doi.org/10.1002/1097-0142(19940701)74:1<182::AID-CNCR2820740129>3.0.CO;2-2

[27]   Steinherz, L.J., Steinherz, P.G., Tan, C.T., Heller, G. and Murphy, M.L. (1991) Cardiac Toxicity 4 to 20 Years after Completing Anthracycline Therapy. JAMA, 266, 1672-1677.
http://dx.doi.org/10.1001/jama.1991.03470120074036

[28]   Healey, B.R.J. and Swain, S.M. (2008) Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clinical Cancer Research, 1, 14-24.

[29]   Hosalkar, H.S., Henderson, K.M., Weiss, A., Donthineni, R. and Lackman, R.D. (2004) Chemotherapy for Bone Sarcoma Does Not Affect Fertility Rates or Childbirth. Clinical Orthopaedics and Related Research, 428, 256-260. Erratum in: Clinical Orthopaedics, 429, 352.
http://dx.doi.org/10.1097/01.blo.0000137547.14953.1e

[30]   Ramalingam, S., Perry, M.C., La Rocca, R.V., Rinaldi, D., Gable, P.S., Tester, W.J. and Belani, C.P. (2008) Comparison of Outcomes for Elderly Patients Treated with Weekly Paclitaxel in Combination with Carboplatin versus the Standard 3-Weekly Paclitaxel and Carboplatin for Advanced Nonsmall Cell Lung Cancer. Cancer, 113, 542-546. http://dx.doi.org/10.1002/cncr.23583

[31]   Weiss, A.J. (1984) Studies on Cardiotoxicity and Antitumor Effect of Doxorubicin Administered Weekly. Cancer Treatment Symposia, 3, 91-94.

[32]   de Nigris, F., Rienzo, M., Schiano, C., Fiorito, C., Casamassimi, A. and Napoli, C. (2008) Prominent Cardioprotective Effects of Third Generation Beta Blocker Nebivolol against Anthracycline-Induced Cardiotoxicity Using the Model of Isolated Perfused Rat Heart. European Journal of Cancer, 44, 334-340. http://dx.doi.org/10.1016/j.ejca.2007.12.010

[33]   Huh, W.W., Jaffe, N., Durand, J.B., Munsell, M.F. and Herzog, C.E. (2010) Comparison of Doxorubicin Cardiotoxicity in Pediatric Sarcoma Patients When Given with Dexrazoxane versus as Continuous Infusion. Pediatric HematologyOncology, 27, 546-557.
http://dx.doi.org/10.3109/08880018.2010.503335

[34]   Tsubaki, M., Komai, M., Itoh, T., Imano, M., Sakamoto, K., Shimaoka, H., Takeda, T., Ogawa, N., Mashimo, K., Fujiwara, D., Mukai, J., Sakaguchi, K., Satou, T. and Nishida, S. (2014) By Inhibiting Src, Verapamil and Dasatinib Overcome Multidrug Resistance via Increased Expression of Bim and Decreased Expressions of MDR1 and Survivin in Human Multidrug-Resistant Myeloma Cells. Leukemia Research, 38, 121-130. http://dx.doi.org/10.1016/j.leukres.2013.10.017

[35]   Mould, E., Berry, P., Jamieson, D., Hill, C., Cano, C., Tan, N., Elliott, S., Durkacz, B., Newell, D. and Willmore, E. (2014) Identification of Dual DNA-PK MDR1 Inhibitors for the Potentiation of Cytotoxic Drug Activity. Biochemical Pharmacology, 88, 58-65. http://dx.doi.org/10.1016/j.bcp.2014.01.001

[36]   Li, J., Xu, L.Z., He, K.L., Guo, W.J., Zheng, Y.H., Xia, P. and Chen, Y. (2001) Reversal Effects of Nomegestrol Acetate on Multidrug Resistance in Adriamycin-Resistant MCF7 Breast Cancer Cell Line. Breast Cancer Research, 3, 253-263. http://dx.doi.org/10.1186/bcr303

[37]   Juvale, K., Stefan, K., Juvale, K., Stefan, K. and Wiese, M. (2013) Synthesis and Biological Evaluation of Flavones and Benzoflavones as Inhibitors of BCRP/ABCG2. European Journal of Medicinal Chemistry, 67, 115-126. http://dx.doi.org/10.1016/j.ejmech.2013.06.035

[38]   Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D.D., Groshen, S., Lyass, O., Henderson, R., Berry, G. and Gabizon, A. (2000) Pegylated Liposomal Doxorubicin (doxil): Reduced Clinical Cardiotoxicity in Patients Reaching or Exceeding Cumulative Doses of 500 mg/m2. Annals of Oncology, 11, 1029-1033. http://dx.doi.org/10.1023/A:1008365716693

[39]   Rafiyath, S.M., Rasul, M., Lee, B., Wei, G., Lamba, G. and Liu, D. (2012) Comparison of Safety and Toxicity of Liposomal Doxorubicin vs. Conventional Anthracyclines: A Meta-Analysis. Experimental Hematology & Oncology, 1, 10. http://dx.doi.org/10.1186/2162-3619-1-10

[40]   Tomita, S., Ishida, M., Nakatani, T., Fukuhara, S., Hisashi, Y., Ohtsu, Y., Suga, M., Yutani, C., Yagihara, T., Yamada, K. and Kitamura, S. (2004) Bone Marrow Is a Source of Regenerated Cardiomyocytes in Doxorubicin-Induced Cardiomyopathy and Granulocyte Colony-Stimulating Factor Enhances Migration of Bone Marrow Cells and Attenuates Cardiotoxicity of Doxorubicin under Electron Microscopy. Journal of Heart and Lung Transplantation, 23, 577-584. http://dx.doi.org/10.1016/j.healun.2003.06.001

[41]   Li, L., Takemura, G., Li, Y., Miyata, S., Esaki, M., Okada, H., Kanamori, H., Ogino, A., Maruyama, R., Nakagawa, M., Minatoguchi, S., Fujiwara, T. and Fujiwara, H. (2007) Granulocyte Colony-Stimulating Factor Improves Left Ventricular Function of Doxorubicin-Induced Cardiomyopathy. Laboratory Investigation, 87, 440-455.

 
 
Top